OUR TECHNOLOGY

A patented formulation process and mixture of two natural and safe compounds which stabilizes the vaccine or bio-therapeutic at up to 40°C as if it were frozen at -80°C.
bt_bb_section_bottom_section_coverage_image

PT-120 ™Formulation Stabilization Technology

The work on PT120 started in the Filipe lab at McMaster University in 2014. During the course of this work, many different substances have been stabilized. Here are a few examples.

RNA

RNA is particularly unstable in the environment. It is prone to degradation by the ubiquitous RNAse enzyme, but also simply degrading by reacting with itself. The pullulan film prevents cleavage through both mechanisms.
Figure 1

Figure 1

Preventing RNA auto-cleavage at pH 7.5. Percentage cleavage of RS1 in solution and in pullulan film.
Figure 2

Figure 2

Preventing RNA auto-cleavage under alkaline conditions. Percentage cleavage of RS2 in alkaline solution and in alkaline pullulan film.

LAV

Viruses are another example of unstable products, specifically in the face of higher temperatures. In the study below, attenuated herpes simplex virus and inactivated influenza A virus were stored in PT120 and also in solution at -80°C and +40°C for 12 weeks. They were then used to inoculate mice and these mice were subsequently challenged with the live virus. The results show clearly that protection by PT120 at 40°C, was as effective as freezing the vaccine at -80°C. The vaccine stored in solution at 40°C was also completely ineffective at protecting the mice.
Figure 1.

Figure 1.

HSV-2 Virus Stability at 25°C. Elarex PT120 outperforms Trehalose 1000-fold at 12 weeks.
Figure 2.

Figure 2.

HSV-2 with Elarex PT120 stored for 8 weeks at 40°C equivalent to storage at -80°C.
Figure 3.

Figure 3.

Inactivated IAV with Elarex PT120 stored for 12 weeks at 40°C equivalent to storage at -80°C.
Figure 4.

Figure 4.

Immune response by ELISA for flu-specific IgG in serum. Equivalent responses for inactivated IAV stored at -80°C and when protected by PT120 at 40°C for 12 weeks.

mRNA-LNPs

mRNA-LNPs have proven their worth in a very short time, and are arguably the most important new vaccine format by a wide margin. We have begun work on stabilizing lipid nanoparticles and their precious mRNA cargo by applying our PT120 technology. While we have not published any data yet, we have promising results that we will share soon. Contact us if you would like to learn more.

LetsConnect

    Name (required)*
    Email (required)*
    Phone (required)*
    Message